Predicta Biosciences GenoPredicta

Predicta Biosciences has launched its first laboratory developed test, GenoPredicta for bone marrow or blood. The whole-genome sequencing test is performed in the company's CLIA-certified laboratory and measures a spectrum of genomic alterations to be used by ordering physicians to molecularly diagnose individuals who have or are at risk for multiple myeloma, as well as to inform therapeutic management. Because it uses WGS, the test can identify prognostic cytogenetic variants that are commonly tested for using FISH assays as well as additional variant types that are not currently tested for that can be relevant for targeted therapy and immunotherapy selection. The company expects to launch a second assay, GenoPredicta for minimal residual disease monitoring later this year.